Aetna · Clinical coverage policy

Aetna Benign Prostatic Hyperplasia coverage criteria

Aetna CPB 0079 covers benign prostatic hyperplasia (BPH) treatments as medically necessary alternatives to TURP, including medical therapy (alpha-blockers, finasteride/dutasteride, tadalafil 5 mg) and a range of procedures (TUIP, TUMT, TUNA/Rezum water vapor, TUVP, laser procedures such as HoLEP/PVP/CLAP/VLAP/TULIP, Aquablation, prostatic urethral lift/UroLift, prostatic arterial embolization, and ultrasonic aspiration), plus device-specific gates for the iTind temporary implant (prostate 25-75 g and no median-lobe obstruction) and the UroLume stent (age/surgical-candidacy and >=2.5 cm prostate length). Many newer or unproven modalities (e.g., HIFU, histotripsy, botulinum toxin, cryoablation, mirabegron, phytotherapy, drug-coated balloons except Optilume for recurrent bulbar strictures, and various molecular/diagnostic tests) are considered experimental, investigational, or unproven. The bulletin is silent on whether precertification is required.

Policy CPB 0079 · Effective · Verify against the current Aetna policy before submitting — view source policy.

Payer

Aetna

Policy

CPB 0079

Prior auth

Confirm

Effective

January 1, 2026

This page reflects the coverage criteria captured from Aetna policy CPB 0079 and may not include every criterion, exception, or code — verify the complete bulletin before submitting.

What this means for the claim

The covered path, the next step to get it approved, and the specific way it denies — built only from this policy.

When does Aetna cover Benign Prostatic Hyperplasia (CPT 52441), and what gets it denied?

Path
Aetna CPB 0079 covers benign prostatic hyperplasia (BPH) treatments as medically necessary alternatives to TURP, including medical therapy (alpha-blockers, finasteride/dutasteride, tadalafil 5 mg) and a range of procedures (TUIP, TUMT, TUNA/Rezum water vapor, TUVP, laser procedures such as HoLEP/PVP/CLAP/VLAP/TULIP, Aquablation, prostatic urethral lift/UroLift, prostatic arterial embolization, and ultrasonic aspiration), plus device-specific gates for the iTind temporary implant (prostate 25-75 g and no median-lobe obstruction) and the UroLume stent (age/surgical-candidacy and >=2.5 cm prostate length). Many newer or unproven modalities (e.g., HIFU, histotripsy, botulinum toxin, cryoablation, mirabegron, phytotherapy, drug-coated balloons except Optilume for recurrent bulbar strictures, and various molecular/diagnostic tests) are considered experimental, investigational, or unproven. The bulletin is silent on whether precertification is required. Coverage criteria include: Aetna considers the following approaches medically necessary for members with benign prostatic hyperplasia (BPH) as alternatives to transurethral resection of the prostate (TURP); Alpha-adrenergic blockers (alfuzosin, doxazosin, silodosin, tamsulosin, terazosin) are medically necessary for BPH; Hormonal manipulation / 5-alpha reductase inhibitors (finasteride, dutasteride, or dutasteride plus tamsulosin) is medically necessary for BPH; Tadalafil 5 mg daily dose is medically necessary for BPH (Note: some plans exclude coverage of tadalafil; check the benefit plan description); Aquablation (AquaBeam, water jet hydrodissection) is medically necessary for BPH; Interstitial laser coagulation of the prostate (ILCP) is medically necessary for BPH; Laser prostatectomy is medically necessary for BPH; Laser-based procedures are medically necessary for BPH (ONE of): contact laser ablation of the prostate (CLAP) OR holmium laser (HoLAP, HoLEP, HoLRP) OR photo-selective laser vaporization of the prostate (PVP) OR transurethral ultrasound-guided laser-induced prostatectomy (TULIP) OR visually-guided laser ablation (VLAP); Prostatic arterial embolization (transcatheter arterial embolization) is medically necessary for BPH; Prostatic urethral lift (UroLift; typically 4 to 6 implants placed into the prostate) is medically necessary for BPH; Transurethral electrovaporization of the prostate (TUVP) is medically necessary for BPH; Transurethral incision of the prostate (TUIP) is medically necessary for BPH; Transurethral microwave thermotherapy (TUMT) is medically necessary for BPH; Transurethral needle ablation (TUNA) / radiofrequency needle ablation (RFNA), including water vapor thermal therapy (Rezum system), is medically necessary for BPH; Ultrasonic aspiration of the prostate is medically necessary for BPH; UroLume Endo-urethral Prosthesis (urethral stent) is medically necessary for BPH when ALL of: member is a man at least 60 years of age OR a man under 60 years of age who is a poor surgical candidate; AND prostate is at least 2.5 cm in length (Note: UroLume is not intended for temporary use); UroLume Endo-urethral Prosthesis is medically necessary for recurrent bulbar urethral stenoses/strictures when previous therapeutic approaches such as dilation, urethrotomy, or urethroplasty have failed; Temporary implanted prostatic device (iTind) is medically necessary for BPH when ALL of: prostate volume is between 25 and 75 g; AND there is a lack of obstruction in the median lobe. Applies to 13 codes: 52441, 52442, 52450, 52601, 52647, 52648, 52649, 53850, 53854, 37243, C9739, C9740, C9769.
Action
Confirm prior-authorization status with Aetna before scheduling — it is code- and plan-specific, and this policy is not an exact authorization source.
Trap
Policy exclusions and limitations: Aetna considers the following experimental, investigational, or unproven for BPH (because the effectiveness has not been established); Absolute ethanol injection (transurethral) is experimental, investigational, or unproven; Acupuncture is experimental, investigational, or unproven; Bipolar plasma enucleation is experimental, investigational, or unproven; Botulinum toxin is experimental, investigational, or unproven; Cryosurgical ablation is experimental, investigational, or unproven; CYP17 rs743572 polymorphism testing is experimental, investigational, or unproven; Drug-coated balloons (DCB) for BPH / bladder neck contracture are experimental, investigational, or unproven (EXCEPT: Optilume drug-coated balloon for one-time treatment of recurrent bulbar urethral strictures); Endoscopic balloon dilation is experimental, investigational, or unproven; High-intensity focused ultrasound (HIFU) is experimental, investigational, or unproven; Histotripsy (non-invasive focused ultrasound) is experimental, investigational, or unproven; Home-based uroflowmetry telemonitoring is experimental, investigational, or unproven; Interleukin-6 (blood or tissue) as a severity indicator is experimental, investigational, or unproven; Intra-prostatic injections of vitamin D3 receptor analogs are experimental, investigational, or unproven; Laser procedures for indications OTHER than those listed as medically necessary are experimental, investigational, or unproven; Luteinizing hormone-releasing hormone antagonists are experimental, investigational, or unproven; Melatonin is experimental, investigational, or unproven; Blood-based microRNAs and seminal cell-free DNA for differential diagnosis are experimental, investigational, or unproven; Minimally invasive laser enucleation of the prostate (MiLEP) is experimental, investigational, or unproven; Mirabegron (Myrbetriq) is experimental, investigational, or unproven; MRI-guided laser focal ablation is experimental, investigational, or unproven; Phytotherapy is experimental, investigational, or unproven; Plasma kinetic vaporization (Gyrus system) is experimental, investigational, or unproven; Plasma miR222-3p for BPH diagnosis is experimental, investigational, or unproven; Prosta-Seq for BPH diagnosis is experimental, investigational, or unproven; Transperineal laser ablation (TLAP / TPLA) with imaging is experimental, investigational, or unproven; Transrectal thermal therapy (microwave, radiofrequency, electrothermal, or HIFU) is experimental, investigational, or unproven; UroLume for indications OTHER than those listed as medically necessary is experimental, investigational, or unproven; Water-induced thermotherapy (hot-water balloon thermoablation) is experimental, investigational, or unproven; XFLO Expander System (Mercury Expander System) is experimental, investigational, or unproven; Tadalafil should not be used in combination with alpha-blockers for the treatment of BPH (contraindication); Tadalafil should not be used in patients taking nitrates (contraindication); Some plans exclude coverage of tadalafil for BPH; coverage is subject to the benefit plan description. Claims may be denied when the requested service falls under these. Some of these are conditional (note the stated exceptions) — confirm specifics against the bulletin.

Source: Aetna CPB 0079 — Benign Prostatic Hyperplasia

Coverage criteria

  • Aetna considers the following approaches medically necessary for members with benign prostatic hyperplasia (BPH) as alternatives to transurethral resection of the prostate (TURP)
  • Alpha-adrenergic blockers (alfuzosin, doxazosin, silodosin, tamsulosin, terazosin) are medically necessary for BPH
  • Hormonal manipulation / 5-alpha reductase inhibitors (finasteride, dutasteride, or dutasteride plus tamsulosin) is medically necessary for BPH
  • Tadalafil 5 mg daily dose is medically necessary for BPH (Note: some plans exclude coverage of tadalafil; check the benefit plan description)
  • Aquablation (AquaBeam, water jet hydrodissection) is medically necessary for BPH
  • Interstitial laser coagulation of the prostate (ILCP) is medically necessary for BPH
  • Laser prostatectomy is medically necessary for BPH
  • Laser-based procedures are medically necessary for BPH (ONE of): contact laser ablation of the prostate (CLAP) OR holmium laser (HoLAP, HoLEP, HoLRP) OR photo-selective laser vaporization of the prostate (PVP) OR transurethral ultrasound-guided laser-induced prostatectomy (TULIP) OR visually-guided laser ablation (VLAP)
  • Prostatic arterial embolization (transcatheter arterial embolization) is medically necessary for BPH
  • Prostatic urethral lift (UroLift; typically 4 to 6 implants placed into the prostate) is medically necessary for BPH
  • Transurethral electrovaporization of the prostate (TUVP) is medically necessary for BPH
  • Transurethral incision of the prostate (TUIP) is medically necessary for BPH
  • Transurethral microwave thermotherapy (TUMT) is medically necessary for BPH
  • Transurethral needle ablation (TUNA) / radiofrequency needle ablation (RFNA), including water vapor thermal therapy (Rezum system), is medically necessary for BPH
  • Ultrasonic aspiration of the prostate is medically necessary for BPH
  • UroLume Endo-urethral Prosthesis (urethral stent) is medically necessary for BPH when ALL of: member is a man at least 60 years of age OR a man under 60 years of age who is a poor surgical candidate; AND prostate is at least 2.5 cm in length (Note: UroLume is not intended for temporary use)
  • UroLume Endo-urethral Prosthesis is medically necessary for recurrent bulbar urethral stenoses/strictures when previous therapeutic approaches such as dilation, urethrotomy, or urethroplasty have failed
  • Temporary implanted prostatic device (iTind) is medically necessary for BPH when ALL of: prostate volume is between 25 and 75 g; AND there is a lack of obstruction in the median lobe

Covered codes

Codes listed in this Aetna policy. Check each one's prior-authorization verdict and Medicare rate:

Frequently asked questions

When does Aetna cover Benign Prostatic Hyperplasia (CPT 52441), and what gets it denied?
Aetna CPB 0079 covers benign prostatic hyperplasia (BPH) treatments as medically necessary alternatives to TURP, including medical therapy (alpha-blockers, finasteride/dutasteride, tadalafil 5 mg) and a range of procedures (TUIP, TUMT, TUNA/Rezum water vapor, TUVP, laser procedures such as HoLEP/PVP/CLAP/VLAP/TULIP, Aquablation, prostatic urethral lift/UroLift, prostatic arterial embolization, and ultrasonic aspiration), plus device-specific gates for the iTind temporary implant (prostate 25-75 g and no median-lobe obstruction) and the UroLume stent (age/surgical-candidacy and >=2.5 cm prostate length). Many newer or unproven modalities (e.g., HIFU, histotripsy, botulinum toxin, cryoablation, mirabegron, phytotherapy, drug-coated balloons except Optilume for recurrent bulbar strictures, and various molecular/diagnostic tests) are considered experimental, investigational, or unproven. The bulletin is silent on whether precertification is required. Coverage criteria include: Aetna considers the following approaches medically necessary for members with benign prostatic hyperplasia (BPH) as alternatives to transurethral resection of the prostate (TURP); Alpha-adrenergic blockers (alfuzosin, doxazosin, silodosin, tamsulosin, terazosin) are medically necessary for BPH; Hormonal manipulation / 5-alpha reductase inhibitors (finasteride, dutasteride, or dutasteride plus tamsulosin) is medically necessary for BPH; Tadalafil 5 mg daily dose is medically necessary for BPH (Note: some plans exclude coverage of tadalafil; check the benefit plan description); Aquablation (AquaBeam, water jet hydrodissection) is medically necessary for BPH; Interstitial laser coagulation of the prostate (ILCP) is medically necessary for BPH; Laser prostatectomy is medically necessary for BPH; Laser-based procedures are medically necessary for BPH (ONE of): contact laser ablation of the prostate (CLAP) OR holmium laser (HoLAP, HoLEP, HoLRP) OR photo-selective laser vaporization of the prostate (PVP) OR transurethral ultrasound-guided laser-induced prostatectomy (TULIP) OR visually-guided laser ablation (VLAP); Prostatic arterial embolization (transcatheter arterial embolization) is medically necessary for BPH; Prostatic urethral lift (UroLift; typically 4 to 6 implants placed into the prostate) is medically necessary for BPH; Transurethral electrovaporization of the prostate (TUVP) is medically necessary for BPH; Transurethral incision of the prostate (TUIP) is medically necessary for BPH; Transurethral microwave thermotherapy (TUMT) is medically necessary for BPH; Transurethral needle ablation (TUNA) / radiofrequency needle ablation (RFNA), including water vapor thermal therapy (Rezum system), is medically necessary for BPH; Ultrasonic aspiration of the prostate is medically necessary for BPH; UroLume Endo-urethral Prosthesis (urethral stent) is medically necessary for BPH when ALL of: member is a man at least 60 years of age OR a man under 60 years of age who is a poor surgical candidate; AND prostate is at least 2.5 cm in length (Note: UroLume is not intended for temporary use); UroLume Endo-urethral Prosthesis is medically necessary for recurrent bulbar urethral stenoses/strictures when previous therapeutic approaches such as dilation, urethrotomy, or urethroplasty have failed; Temporary implanted prostatic device (iTind) is medically necessary for BPH when ALL of: prostate volume is between 25 and 75 g; AND there is a lack of obstruction in the median lobe. Applies to 13 codes: 52441, 52442, 52450, 52601, 52647, 52648, 52649, 53850, 53854, 37243, C9739, C9740, C9769. Confirm prior-authorization status with Aetna before scheduling — it is code- and plan-specific, and this policy is not an exact authorization source. Policy exclusions and limitations: Aetna considers the following experimental, investigational, or unproven for BPH (because the effectiveness has not been established); Absolute ethanol injection (transurethral) is experimental, investigational, or unproven; Acupuncture is experimental, investigational, or unproven; Bipolar plasma enucleation is experimental, investigational, or unproven; Botulinum toxin is experimental, investigational, or unproven; Cryosurgical ablation is experimental, investigational, or unproven; CYP17 rs743572 polymorphism testing is experimental, investigational, or unproven; Drug-coated balloons (DCB) for BPH / bladder neck contracture are experimental, investigational, or unproven (EXCEPT: Optilume drug-coated balloon for one-time treatment of recurrent bulbar urethral strictures); Endoscopic balloon dilation is experimental, investigational, or unproven; High-intensity focused ultrasound (HIFU) is experimental, investigational, or unproven; Histotripsy (non-invasive focused ultrasound) is experimental, investigational, or unproven; Home-based uroflowmetry telemonitoring is experimental, investigational, or unproven; Interleukin-6 (blood or tissue) as a severity indicator is experimental, investigational, or unproven; Intra-prostatic injections of vitamin D3 receptor analogs are experimental, investigational, or unproven; Laser procedures for indications OTHER than those listed as medically necessary are experimental, investigational, or unproven; Luteinizing hormone-releasing hormone antagonists are experimental, investigational, or unproven; Melatonin is experimental, investigational, or unproven; Blood-based microRNAs and seminal cell-free DNA for differential diagnosis are experimental, investigational, or unproven; Minimally invasive laser enucleation of the prostate (MiLEP) is experimental, investigational, or unproven; Mirabegron (Myrbetriq) is experimental, investigational, or unproven; MRI-guided laser focal ablation is experimental, investigational, or unproven; Phytotherapy is experimental, investigational, or unproven; Plasma kinetic vaporization (Gyrus system) is experimental, investigational, or unproven; Plasma miR222-3p for BPH diagnosis is experimental, investigational, or unproven; Prosta-Seq for BPH diagnosis is experimental, investigational, or unproven; Transperineal laser ablation (TLAP / TPLA) with imaging is experimental, investigational, or unproven; Transrectal thermal therapy (microwave, radiofrequency, electrothermal, or HIFU) is experimental, investigational, or unproven; UroLume for indications OTHER than those listed as medically necessary is experimental, investigational, or unproven; Water-induced thermotherapy (hot-water balloon thermoablation) is experimental, investigational, or unproven; XFLO Expander System (Mercury Expander System) is experimental, investigational, or unproven; Tadalafil should not be used in combination with alpha-blockers for the treatment of BPH (contraindication); Tadalafil should not be used in patients taking nitrates (contraindication); Some plans exclude coverage of tadalafil for BPH; coverage is subject to the benefit plan description. Claims may be denied when the requested service falls under these. Some of these are conditional (note the stated exceptions) — confirm specifics against the bulletin.
Does Aetna require prior authorization for Benign Prostatic Hyperplasia?
Confirm prior-authorization status with Aetna before scheduling — it is code- and plan-specific, and this policy is not an exact authorization source.
What does Aetna exclude for Benign Prostatic Hyperplasia?
Policy exclusions and limitations: Aetna considers the following experimental, investigational, or unproven for BPH (because the effectiveness has not been established); Absolute ethanol injection (transurethral) is experimental, investigational, or unproven; Acupuncture is experimental, investigational, or unproven; Bipolar plasma enucleation is experimental, investigational, or unproven; Botulinum toxin is experimental, investigational, or unproven; Cryosurgical ablation is experimental, investigational, or unproven; CYP17 rs743572 polymorphism testing is experimental, investigational, or unproven; Drug-coated balloons (DCB) for BPH / bladder neck contracture are experimental, investigational, or unproven (EXCEPT: Optilume drug-coated balloon for one-time treatment of recurrent bulbar urethral strictures); Endoscopic balloon dilation is experimental, investigational, or unproven; High-intensity focused ultrasound (HIFU) is experimental, investigational, or unproven; Histotripsy (non-invasive focused ultrasound) is experimental, investigational, or unproven; Home-based uroflowmetry telemonitoring is experimental, investigational, or unproven; Interleukin-6 (blood or tissue) as a severity indicator is experimental, investigational, or unproven; Intra-prostatic injections of vitamin D3 receptor analogs are experimental, investigational, or unproven; Laser procedures for indications OTHER than those listed as medically necessary are experimental, investigational, or unproven; Luteinizing hormone-releasing hormone antagonists are experimental, investigational, or unproven; Melatonin is experimental, investigational, or unproven; Blood-based microRNAs and seminal cell-free DNA for differential diagnosis are experimental, investigational, or unproven; Minimally invasive laser enucleation of the prostate (MiLEP) is experimental, investigational, or unproven; Mirabegron (Myrbetriq) is experimental, investigational, or unproven; MRI-guided laser focal ablation is experimental, investigational, or unproven; Phytotherapy is experimental, investigational, or unproven; Plasma kinetic vaporization (Gyrus system) is experimental, investigational, or unproven; Plasma miR222-3p for BPH diagnosis is experimental, investigational, or unproven; Prosta-Seq for BPH diagnosis is experimental, investigational, or unproven; Transperineal laser ablation (TLAP / TPLA) with imaging is experimental, investigational, or unproven; Transrectal thermal therapy (microwave, radiofrequency, electrothermal, or HIFU) is experimental, investigational, or unproven; UroLume for indications OTHER than those listed as medically necessary is experimental, investigational, or unproven; Water-induced thermotherapy (hot-water balloon thermoablation) is experimental, investigational, or unproven; XFLO Expander System (Mercury Expander System) is experimental, investigational, or unproven; Tadalafil should not be used in combination with alpha-blockers for the treatment of BPH (contraindication); Tadalafil should not be used in patients taking nitrates (contraindication); Some plans exclude coverage of tadalafil for BPH; coverage is subject to the benefit plan description. Claims may be denied when the requested service falls under these. Some of these are conditional (note the stated exceptions) — confirm specifics against the bulletin.

Source

Aetna CPB 0079 — Benign Prostatic Hyperplasia

Related

Need this Aetna approval drafted?

Ask D3 builds the documentation checklist and a ready-to-send request from this policy's criteria — cited, free, no signup.

Ask D3 Free

Coverage disclaimer

This page summarizes Aetna clinical-coverage criteria extracted from policy CPB 0079 for educational purposes. Coverage policies change and vary by individual plan. Always verify against Aetna's current policy before performing a procedure or submitting a claim. d3rx is not responsible for claim denials or reimbursement issues.